Prevalence of Metabolic Syndrome in HIV-Infected Cameroonian Patients
Henriette Thérèse Dimodi, Lucien Sone Etame, Boris Signing Nguimkeng, Florine Essouman Mbappe, Nadine Essola Ndoe, Jacob Nkougni Tchinda, J. Justin Abega Ebene, Françoise Raïssa Ntentié, G. Boris Azantsa Kingue, Mary-Ann Mbong Angie, Ghislain Djiokeng Paka, Charles Kouanfack, Judith Laure Ngondi, Julius Oben Enyong
Central Hospital, Yaounde, Cameroon.
Department of Biochemistry, Yaounde I University, Yaounde, Cameroon.
Department of Biochemistry, Yaounde I University, Yaounde, Cameroon;Centre for Food and Nutrition Research (CRAN), Institute of Medical Research and Medicinal Plants Study (IMPM), Ministry of Scientific Research and Innovation, Yaounde, Cameroon.
Department of Biochemistry, Yaounde I University, Yaounde, Cameroon;Department of Biochemistry and Molecular Biology, University of Buea, Buea, Cameroon.
Department of Biochemistry, Yaounde I University, Yaounde, Cameroon;Higher Teacher’s Training College (ENS), University of Maroua, Maroua, Cameroon.
Department of Biochemistry, Yaounde I University, Yaounde, Cameroon;INRS-Institut Armand Frappier, Laval, Québec, Canada.
DOI: 10.4236/wja.2014.41011   PDF   HTML     5,003 Downloads   7,159 Views   Citations


Aims: Metabolic complications related to antiretroviral therapy are rarely investigated among HIV-infected patients in Cameroon. The study reports the prevalence of metabolic syndrome and its individual components among HIV-infected Cameroonians. Materials and Methods: We conducted a prospective, cross-sectional study of the prevalence of metabolic syndrome among 492 patients (338 women, 117 men; age range 20 years) recruited at a reference centre, the day hospital, Central Hospital in Yaounde between September 2009 and September 2010. Metabolic syndrome was defined according to IDF (International Diabetes Federation) and NCEP ATP III (National Cholesterol Education Program Adult Treatment Panel III) criteria relative to obesity, glycemic, lipid, arterial blood pressure parameters. Results: The prevalence of metabolic syndrome was 32.8% according to IDF and 30.7% by NCEP (p = 0.0001). The prevalences of individual components according to IDF and NCEP were as follows: abdominal obesity (40.5%; 26.9% respectively), hypertriglyceridemia (55.5%), low HDL cholesterol (42.5%), systolic hypertension (38.2%) diastolic hypertension (28.5%), hyperglycemia (31.2%; 1.3% p = 0.0001). The prevalence of metabolic syndrome was 36% in patients under HAART, 23.4% in naive, (p = 0.0001). Conclusion: The prevalence of metabolic syndrome depends on the presence and the type of HAART used, the definition and the gender.

Share and Cite:

Dimodi, H. , Etame, L. , Nguimkeng, B. , Mbappe, F. , Ndoe, N. , Tchinda, J. , Ebene, J. , Ntentié, F. , Kingue, G. , Angie, M. , Paka, G. , Kouanfack, C. , Ngondi, J. and Enyong, J. (2014) Prevalence of Metabolic Syndrome in HIV-Infected Cameroonian Patients. World Journal of AIDS, 4, 85-92. doi: 10.4236/wja.2014.41011.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Sterne, J.A., Hernan, M.A., Ledergerber, B., Tilling, K., Weber, R., Sendi, P., et al. (2005) Long-Term Effectiveness of Potent Antiretroviral Therapy in Preventing AIDS and Death: A Prospective Cohort Study. Lancet, 366, 378-384.
[2] Hadigan, C., Meigs, J.B., Corcoran, C., Rietschel, P., Piecuch, S., Basgoz, N., et al. (2001) Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and Lipodystrophy. Clinical Infectious Diseases, 32, 130-139.
[3] Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D.J. and Cooper, D.A. (1998) A Syndrome of Peripheral Lipodystrophy, Hyperlipidaemia and Insulin Resistance in Patients Receiving HIV Protease Inhibitors. AIDS, 12, 51-58.
[4] Grundy, S.M., Brewer, H.B., Cleeman, J.I., Smith, S.C. and Lenfant, C. (2004) The American Heart Association, the National Heart, Lung and Blood Institute: Definition of Metabolic Syndrome: Report of the National Heart Association Conference on Scientific Issues Related to Definition. Circulation, 109, 433-438.
[5] Lakka, H.M., Laaksonen, D., Laaka, T.A., Niskanen, L.K., Kumpusalo, E., Tuomilehto, J., et al. (2002) The Metabolic Syndrome and Total and Cardiovascular Disease Mortality in Middle-Aged Men. JAMA, 288, 2709-2716.
[6] Reaven, G.M. (2006) The Metabolic Syndrome: Is This Diagnosis Necessary? The American Journal of Clinical Nutrition, 83, 1237-1247.
[7] Saves, M., Chêne, G., Ducimetiere, P., Leport, C., Le Moal, G. and Amouyel, P. (2003) Risk Factor for Coronary Heart Diseases in Patients Treated for HIV-Infection Compared with the General Population. Clinical Infectious Diseases, 37, 292-298.
[8] Mondy, K., Overton, E., Grubb, J., Tong, S., Seyfried, W., Powerderly, W. and Yarasheski, K. (2007) Metabolic Syndrome in HIV-Infected Patients from an Urban, Midwestern US OUTPATIENT Population. Clinical Infectious Diseases, 44, 726-734.
[9] Jerico, C., Knobel, H., Montero, M., Knobel, H., Ordonez-Llanos, J., Guelar, A, et al. (2005) Metabolic Syndrome among HIV-Infected Patients: Prevalence, Characteristics, and Related Factors. Diabetes Care, 28, 144-149.
[10] Sales, S., Campa, A., Makhema, J., Dusara, P., Tsalaile, L., Burns, P.J., et al. (2009) Metabolic Syndrome in HIV + Asymptomatic Adults in Botswana, Africa. The Journal of the Federation of American Societies for Experimental Biology, 918, 4.
[11] Mhlabi, D.B. (2011) Metabolic Syndrome among People with Human Immunodeficiency Virus on Anti-retroviral Therapy at Princess Marina Hospital in Gaborone-Botswana.
[12] Trinder, P. (1969) Determination of Blood Glucose Using an Oxydase-Peroxydase System with a Non Carcinogenic Chromogen. Journal of Clinical Pathology, 22, 158-161.
[13] Roeschlau, P., Bernt, E. and Gruber, W.A. (1974) Enzymatic Analysis of Total Cholesterol. Clinical Biochemistry, 12, 226.
[14] Buccolo, G. and David, H. (1973) Quantitative Determination of Serum Triglycerides by the Use of Enzymes. Clinical Chemistry, 19, 476-482.
[15] Friedwald, W.T., Levy, R.I. and Fredrickson, D.S. (1972) Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, without Use of Preparative Ultracentrifuge. Clinical Chemistry, 18, 499-502.
[16] NCEP-ATP III (2001) Executive Summary of the Third Report of The National Cholesterol Education Program in Adults (Adult Treatment Panel III). Journal of the American Medical Association, 285, 2486-2497.
[17] The International Diabetes Federation (2005) The IDF Consensus Worldwide Definition of Metabolic Syndrome.
[18] Worm, S.W., Friis-Moller, N., Bruyand, M., D’Arminio Monforte, A., Rickenbach, M., Reiss, P., et al. (2010) High Prevalence of the Metabolic Syndrome in HIV-Infected Patients: Impact of Different Definitions of the Metabolic Syndrome. AIDS, 24, 427-435.
[19] Enyegue, D.M., Ngondi, J.L., Fomekong, G.I., Agbor, G. and Oben, J.E. (2008) Prediction and Prevalence of Metabolic Syndrome in Overweight and Obese Subject in Cameroon’. International Journal of Biomedical and Pharmaceutical Sciences, 2, 117-121.
[20] EDSC III (2004) Institut National de la Statistique, Troisième Enquête Démographique Santé, Loi n° 96, 12 du 5 Aoû t 1996 portant Loi-c, 250 p.
[21] Ford, E.S., Gilles, W.H. and Dietz, W.H. (2002) Prevalence of the Metabolic Syndrome among US Adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA, 287, 356-359.
[22] Villamar, M.F., Albuja, A.C. and Salas, N.I. (2011) Metabolic Syndrome among HIV-Infected Outpatients from a Hospital in Quito, Ecuador: A Cross Sectionnal Study. Revista Panamericana Infectologia, 13, 12-18.
[23] Alencastro, P.R., Wolff, F.H., Oliveira, R.R., Ikeda, M.L., Barcellos, N.T., Brandão, A.B. and Fuchs, S.C. (2012) Metabolic Syndrome and Population Attributable Risk among HIV) AIDS Patients: Comparison between NCEPATPIII, IDF and AHA) NHLBI Definitions. AIDS Research and Therapy, 9, 29.
[24] Garcia-Garcia, E., De la Liata-Romero, M., Kaufer-Horwitz, M., Tusié-Luna, M.T., Calzada-Leon, R., VasquezVelazquez, V., et al. (2008) La Obesidad Y el Sindrome Metabolico como Problema de Salud Publica. Una Reflexion. Salud Pública de México, 50, 530-547.
[25] Grunfeld, C., Pang, M., Doerrler, W., Shigenaga, J.K., Jensen, P. and Feingold, K.R. (1992) Lipids, Lipoproteins, Triglyceride Clearance, and Cytokines in Human Immunodeficiency Virus Infection and the Acquired Immunodeficiency Syndrome. The Journal of Clinical Endocrinology and Metabolism, 74, 1045-1052.
[26] Jacobson, D.L., Knox, T., Spiegelman, D., Skinner, S., Gorbach, S.L. and Wanke, C. (2005). Prevalence and Evolution of Fat Atrophy and Fat Deposition in a Cohort of HIV-Infected Men and Women. Clinical Infectious Diseases, 40, 1837-1845.
[27] Grinspoon, S. and Carr, A. (2005) Cardiovascular Risk and Body Fat Abnormalities in HIV-Infected Adults. The New England Journal of Medicine, 352, 48-62.
[28] Riddler, S.A., Li, X., Chu, H., Kingsley, S.A., Dobs, A. and Evans, R. (2007) Longitudinal Changes in Serum Lipids among HIV-Infected Men on Highly Active Antiretroviral Therapy. HIV Medicine, 8, 280-287.
[29] Samaras, K. (2007) Metabolic Consequences and Therapeutic Options in Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus-1 Infection. Journal of Antimicrobial Therapy Chemotherapy, 10, 1093-1100.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.